To explore the differential diagnostic approach for newly developed adnexal masses detected during follow-up after treatment for malignant ovarian germ cell tumors.
Key Findings:
The mass decreased to 1.4 × 0.9 cm after three cycles of GnRH-a therapy.
At one-year follow-up, there was no evidence of disease progression, and ovarian reserve was preserved.
Interpretation:
Remove unsupported claims about hormonal therapy as an alternative to surgery.
Limitations:
The diagnosis remains clinical due to the absence of histological confirmation.
Limited clinical experience exists regarding conservative management strategies in this specific scenario.
Conclusion:
Remove general statements about monitoring and individualized management strategies.
